Efficient synthesis and molecular docking of new organoselenium and organosulphur compounds as dual inhibitors for the therapy of Alzheimer's disease as well as Diabetes Mellitus

Abstract

There are several oxidative stress-related pathways interconnecting Alzheimer's disease and type II diabetes, two public health problems worldwide. Therefore, development of potential multifunctional agents for dual therapy of AD and T2D has received much attention. The present study was aimed to synthesize a new selenocarbonyl and thiocarbonyl compounds and evaluating multifunctional ability of them in the AD and T2D dual therapy. [(PhP(Se)(μ-Se)]2, the selenium counterpart of the well-known sulfur transfer Lawesson's reagent, is a useful reagent for the synthesis of selenocarbonyl compounds. For the conversion of various carbonyl compounds into thiocarbonyl derivatives was formulated by its reaction with LR, [(p-MeOC6H4)P(S)(μ-S)]2. The reactions are carried out under mild conditions and afforded the seleno and thio compounds in good yields. By measuring the newly created compounds' overall antioxidant capacity, iron-reducing ability, and scavenging activity against DPPH and ABTS radicals, they were investigated as antioxidant molecules. Additionally, all the compounds were subjected to further investigation by testing their acetylcholinesterase, α-amylase and α-glucosidase inhibiting activity. According to our findings, the amide derivatives exhibited more promising biological inhibitory actions in comparison to the other compounds. With a total antioxidant capacity (TAC) of 75.11 ± 0.04 mg gallic acid/gm, an iron-reducing power (IRP) of 69.86 ± 0.04 µg/mL, a DPPH radical-scavenging activity (%) of 55.89 ± 0.03 (IC50 = 6.19 ± 0.03 µg/ml), and an ABTS radical-scavenging activity (%) of 61.14 ± 0.03 (IC50 = 4.97 ± 0.06 µg/mL), benzoselenoamide derivative 11b in particular showed the highest antioxidant activities when compared to ascorbic acid. It also affected the activity of acetylcholinesterase through competitive inhibition, which was on par with Donepezil as indicated by in vitro percentage of inhibition 57.44 ± 0.07 % (IC50 = 5.13 ± 0.03 µg/mL). Additionally, it exhibited a comparable level of inhibition to Acarbose in the in vitro percentage of inhibition for α-amylase and α-glucosidase activity, 53.17 ± 0.03 (IC50 = 4.32 ± 0.02) and 42.92 ± 0.03 (IC50 = 2.99 ± 0.02) respectively. Furthermore, molecular docking calculations were made to explain the dual inhibitors for the therapy of Alzheimer's as well as Diabetes Mellitus for all synthesized compounds. In silco docking results revealed that compound 11b were the top docked bioactive compounds against the target proteins (AChE as a cholinergic enzyme and 11-Beta-Hydroxysteroid dehydrogenase-1(11β-HSD1)). After these calculations, ADMET analysis was performed to examine the drug properties of all novel compounds. Overall, the results demonstrated that the organoselenium-based compounds might serve as possible drugs for the therapy of Alzheimer's disease as well as Diabetes Mellitus.